Presence of Tumour and Higher Levels of LAG3-positive T-cells in the Blood May Be Necessary to Derive Clinical Benefit with Nivolumab Plus Relatlimab Over Nivolumab in Melanoma By Ogkologos - November 11, 2025 141 0 Facebook Twitter Google+ Pinterest WhatsApp Primary results of RELATIVITY-098 and translational evidence from RELATIVITY-098 and RELATIVITY-047 studies Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Tables Turned June 23, 2020 Why people and culture matter in research August 10, 2021 Skull Implant Delivers Drugs with Precision, Offering Hope for Parkinson’s, Cancer,... February 28, 2019 Four randomized prospective degree compared 90 days regarding neoadjuvant ADT observed... July 21, 2023 Load more HOT NEWS Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... After Battling Breast Cancer and Infertility, Mom Welcomes Miracle Baby Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... How Music Can Help You Cope During Cancer: An Expert Perspective
